Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

Abstract

Bevacizumab administered in combination with 5-fluorouracil/leucovorin-based chemotherapy 28-60 days after primary cancer surgery caused no increased risk of wound healing complications compared with chemotherapy alone. While wound healing complications were increased in patients who had major surgery during bevacizumab therapy, the majority of bevacizumab-treated patients experienced no complications.

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

“…The use of bevacizumab was associated with a 3.1% risk for severe bleeding (versus 2.5% for placebo) and a 1.5% rate of gastrointestinal perforation (versus none for placebo). Other grade Ն3 toxicities attributed to bevacizumab included arterial thromboembolic events (2% versus 1%), wound-healing complications (1.3% versus 0.5), and proteinuria (any proteinuria, 26% versus 21%, but no difference in grade 2 or 3 proteinuria) [1,65,66]. The incidence rates of adverse events were similar in the NO16966 clinical trial (Table 4 and Fig.…”

Current role of antibody therapy in patients with metastatic colorectal cancer

“…A pooled analysis of AVF 2107 and AVF 2192 (Scappaticci et al, 2005) assessed wound healing complications in patients who underwent surgery 28-60 days before study treatment (patients who had undergone major surgery within 28 days were not eligible for enrolment). The risk of wound healing complications was not significantly increased in patients receiving Bv at least 4 weeks after surgery.…”

Management of advanced colorectal cancer: state of the art

“…The use of bevacizumab has been associated with a low level of gastrointestinal perforation events (Kozloff et al, 2006) and some concern has been expressed as to whether anti-VEGF therapy might inhibit wound healing (Scappaticci et al, 2005). This concern led to the recommendation that a patient should not undergo elective hepatic resection during or within 8 weeks of bevacizumab treatment .…”